Levofloxacin

證據等級: L5

預測適應症: 10 個

Levofloxacin: From Bacterial Infections to Monoclonal Gammopathy (Infection Prophylaxis)

One-Sentence Summary

Levofloxacin is a fluoroquinolone antibiotic originally used to treat bacterial infections. Across 10 TxGNN-predicted indications screened in this evidence pack, most show no supporting clinical or literature evidence (Hold), but the model's prediction for Monoclonal Gammopathy — specifically as infection prophylaxis in newly diagnosed multiple myeloma — is backed by a completed Phase 3 RCT (TEAMM) and 20 supporting publications, making it the strongest candidate in this batch.

Quick Overview

Item	Content
Original Indication	Bacterial infections (fluoroquinolone antibiotic); no Taiwan-specific approved indication text on file — drug is currently unmarketed in Taiwan
Predicted New Indication	Monoclonal Gammopathy (infection prophylaxis during myeloma treatment)
TxGNN Prediction Score	99.81%
Evidence Level	L1
Taiwan Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, a structured DrugBank mechanism-of-action record is not available (data gap). Based on the pharmacology already referenced within this evidence pack's own repurposing rationale, Levofloxacin is a broad-spectrum fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, giving it bactericidal activity against a wide range of gram-negative and gram-positive organisms.

Patients with monoclonal gammopathy (particularly newly diagnosed multiple myeloma) have profound humoral immunodeficiency from suppressed normal immunoglobulin production, compounded by chemotherapy-induced neutropenia. Roughly a quarter of newly diagnosed myeloma patients develop a serious infection within 3 months of diagnosis. Levofloxacin's role here is infection prophylaxis during the vulnerable induction/transplant period, not a disease-modifying therapy for the gammopathy itself — the TEAMM trial and subsequent literature support this as a supportive-care intervention rather than a treatment targeting the underlying plasma cell disorder.

This distinction matters for scoping: the mechanistic link is indirect (anti-infective support in an immunocompromised population) rather than a direct antibody/plasma-cell pathway effect, so any recommendation must be framed as "infection prophylaxis in monoclonal gammopathy patients," not "treatment of monoclonal gammopathy."

Clinical Trial Evidence

Currently no related clinical trials registered (no ClinicalTrials.gov or ICTRP records found in this evidence pack for this indication; the pivotal TEAMM trial is documented via literature/HTA report below rather than a registry entry).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31668592	2019	RCT (Phase 3)	Lancet Oncology	TEAMM trial: levofloxacin prophylaxis in newly diagnosed myeloma reduced febrile episodes/infections vs placebo without significantly increasing C. difficile or resistant-organism carriage
31690402	2019	RCT (HTA monograph)	Health Technol Assess	Full technology assessment report of the TEAMM RCT, evaluating antibiotic prophylaxis to prevent infection in newly diagnosed symptomatic myeloma
25212681	2014	RCT	Int J Hematol	Prophylactic oral levofloxacin reduced severe infections in myeloma patients on bortezomib-based regimens at high risk from lymphocytopenia
26150022	2015	RCT/Comparative cohort	Biol Blood Marrow Transplant	Levofloxacin prophylaxis before vs after implementation reduced bloodstream infection and fever/neutropenia rates in autologous HSCT for myeloma
32172361	2020	Review	Curr Hematol Malig Rep	Supportive care review in multiple myeloma covering infection prevention among other management domains
37573150	2023	Cohort study	Transpl Infect Dis	Characterizes infectious complications after autologous HSCT in myeloma, comparing outcomes with/without levofloxacin prophylaxis
29080369	2018	Comparative cohort	Clin Transplant	Retrospective comparison of ciprofloxacin vs levofloxacin prophylaxis in autologous HSCT for myeloma; compared breakthrough infection rates
32304873	2020	Retrospective review	Biol Blood Marrow Transplant	Reassesses fluoroquinolone prophylaxis value in autologous stem-cell transplantation, comparing myeloma (prophylaxis) vs lymphoma (no prophylaxis) cohorts
15791505	2005	Cohort study	Clin Infect Dis	Foundational study showing fluoroquinolone prophylaxis reduces infection-related mortality in neutropenic patients with hematologic malignancies
25591868	2016	Case report (safety)	J Oncol Pharm Pract	Reports acute kidney injury from crystal nephropathy in a myeloma patient on concurrent pomalidomide and levofloxacin — relevant safety signal for this population

Taiwan Market Information

Levofloxacin currently holds no marketing authorization in Taiwan (0 licenses on file, market status: 未上市). No product/dosage-form data is available to tabulate.

Safety Considerations

Please refer to the package insert for safety information. (No structured key-warning, contraindication, or drug-interaction data is currently available in this evidence pack — the Taiwan package insert has not yet been retrieved.)

Other Predicted Indications Screened (This Batch)

For transparency, this evidence pack screened 10 TxGNN-predicted indications for levofloxacin. Only two reached an actionable evidence tier; the remaining eight had no clinical trial or literature support and are held.

Rank	Disease	TxGNN Score	Evidence Level	Recommendation
1	Punctate epithelial keratoconjunctivitis	99.92%	L4	Hold (sole literature source describes microsporidial, not bacterial, etiology — mechanistic mismatch)
7	Monoclonal gammopathy (featured above)	99.81%	L1	Proceed with Guardrails
9	Septicemic plague	99.80%	L2	Proceed with Guardrails — evidence from FDA Animal Rule primate/rodent efficacy studies; already an approved US indication for plague, though human RCTs are not ethically feasible
5	Blood group incompatibility	99.85%	L4	Hold (only literature is an incidental case report of infection during ABO-incompatible transplant workup, not a causal link)
2	Hyperamylasemia	99.90%	L5	Hold (no evidence)
3	Polyclonal hyperviscosity syndrome	99.90%	L5	Hold (no evidence)
4	Congenital analbuminemia	99.89%	L5	Hold (no mechanistic plausibility)
6	Premalignant hematological system disease	99.83%	L5	Hold (label too nonspecific)
8	Hematological disease with acquired peripheral neuropathy	99.80%	L5	Hold (fluoroquinolones carry a known peripheral neuropathy risk — direction contradicts the prediction)
10	Congenital hematological disorder	99.72%	L5	Hold (label too nonspecific)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The monoclonal gammopathy prediction is supported by a completed Phase 3 RCT (TEAMM) plus multiple corroborating cohort studies, establishing levofloxacin's value as infection prophylaxis during myeloma induction/transplant, not as disease-modifying therapy. This is meaningfully stronger evidence than any other candidate in this batch, but the drug is currently unmarketed in Taiwan and a Blocking data gap (DG001: TFDA package insert unavailable) prevents even the initial S1 safety screen from being completed.

To proceed, the following is needed:

Retrieve the Taiwan/TFDA package insert (DG001, Blocking) — required before any S1 safety assessment can proceed
Obtain a structured DrugBank MOA record (DG002)
Scope the indication precisely as "infection prophylaxis in monoclonal gammopathy patients undergoing chemotherapy/HSCT," not treatment of the gammopathy itself
Evaluate the Taiwan registration/import pathway, since the drug currently has zero local marketing authorizations
Track septicemic plague (L2, US Animal Rule precedent) as a secondary candidate in parallel, given its distinct regulatory pathway and biodefense relevance
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.